XML 67 R56.htm IDEA: XBRL DOCUMENT v3.25.2
License Agreements - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 188 Months Ended
May 11, 2025
Nov. 30, 2009
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Dec. 31, 2024
License Agreements                  
Contract dispute settlement     $ 242,251   $ 0 $ 242,251 $ 0    
Total revenues     1,215,529   1,043,759 2,268,427 1,924,648    
United States                  
License Agreements                  
Total revenues     1,132,353   989,029 2,113,910 1,817,193    
JAKAFI                  
License Agreements                  
Total revenues     763,788   705,973 1,473,200 1,277,812    
Novartis | JAKAFI                  
License Agreements                  
Royalties payable       $ 537,100          
Litigation settlement, amount awarded to other party $ 280,000                
Royalty rate payable, percent reduction (as a percent) 50.00%                
Decrease in royalties payable       $ 14,900          
Contract dispute settlement     242,200     242,200      
Novartis | JAKAFI | United States                  
License Agreements                  
Royalties payable     18,700     18,700   $ 18,700 $ 507,400
Total revenues     18,700   34,600 48,500 57,600    
Novartis | JAKAVI                  
License Agreements                  
Total revenues     109,700   99,300 201,900 188,900    
Novartis | TABRECTA                  
License Agreements                  
Total revenues     $ 6,600   $ 5,300 $ 13,000 $ 10,500    
Maximum | Novartis | JAKAVI                  
License Agreements                  
Royalty payments on future global net sales (as a percent)           14.00%      
Minimum | Novartis | JAKAVI                  
License Agreements                  
Royalty payments on future global net sales (as a percent)           12.00%      
Development Milestones | Novartis                  
License Agreements                  
Amount recognized and received for the achievement of a predefined milestone               157,000  
Development Milestones | Maximum | Novartis                  
License Agreements                  
Upfront and immediate milestone payment to be received under license agreement   $ 174,000              
Regulatory Milestones | Novartis                  
License Agreements                  
Amount recognized and received for the achievement of a predefined milestone               345,000  
Regulatory Milestones | Maximum | Novartis                  
License Agreements                  
Upfront and immediate milestone payment to be received under license agreement   495,000              
Commercialization Milestones | Novartis                  
License Agreements                  
Amount recognized and received for the achievement of a predefined milestone               $ 200,000  
Commercialization Milestones | Maximum | Novartis                  
License Agreements                  
Upfront and immediate milestone payment to be received under license agreement   500,000              
Development and Regulatory Milestones | Maximum | Novartis | GVHD                  
License Agreements                  
Upfront and immediate milestone payment to be received under license agreement   $ 75,000